Selective JAK inhibitors with a more specific anti-JAK-1 (e.g., filgotinib and upadacitinib [100]) activity could be promising to narrow the activity and improve safety, but inhibition of JAK2, by partially blocking NF-kβ pathway, could be relevant in SAVI [101]. This evidence concerns the gene JAK2 and STING-associated vasculopathy with onset in infancy.